Screener
Candel Therapeutics, Inc. CADL Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Interest expense | (1,564) | (306) |
| Change in fair value of warrant liabilities | 7,643 | 14,881 |
| Total other income, net | 7,423 | 15,509 |
| Net income (loss) and comprehensive income (loss) | $(8,861) | $7,379 |
| Net income (loss) per share, basic | $(0.14) | $0.15 |
| Weighted-average common shares outstanding, basic | 62,361,897 | 50,482,278 |
| Net income (loss) per share, diluted | $(0.14) | $0.13 |
| Weighted-average common shares outstanding, diluted | 62,361,897 | 54,765,842 |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s shares (diluted)?
- Candel Therapeutics, Inc. (CADL) reported shares (diluted) of 62.4M in Q1 2026.
- How has Candel Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Candel Therapeutics, Inc.'s shares (diluted) increased by 13.9% year-over-year, from 54.8M to 62.4M.
- What is the long-term trend for Candel Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s shares (diluted) has grown at a 34.4% compound annual growth rate (CAGR), from 65.6M to 214.1M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Candel Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude